drugset / Trial / NCT00475371
A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males
Non-randomizedSingle-groupOpen-labelTreatment
Summary
26 subjects will be enrolled into 5 different dose groups. The trial will consist of a screening, a dosing and a follow-up visit. Dosing at visit 2, of MKC253 Inhalation Powder, Glucagon-Like Peptide-1 (GLP-1) will be given at 5 dose levels.
Timeline
- Start
- 2007-04
- Primary completion
- 2007-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GLP-1 (7-36) amide | Unknown | 0.05 mg | Inhaled |
| Subject | GLP-1 (7-36) amide | Unknown | 0.45 mg | Inhaled |
| Subject | GLP-1 (7-36) amide | Unknown | 0.75 mg | Inhaled |
| Subject | GLP-1 (7-36) amide | Unknown | 1.05 mg | Inhaled |
| Subject | GLP-1 (7-36) amide | Unknown | 1.5 mg | Inhaled |